Amundi Asset Management US’s Ligand Pharmaceuticals LGND Stock Holding History

Amundi Asset Management US’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-240	Closed	-$14K	–	1537
2020 Q3	$14K	Sell	240 -2,726	-92%	-$186K	﹤0.01%	1506
2020 Q2	$207K	Buy	+2,966	New	+$188K	﹤0.01%	1377
2020 Q1	–	Sell	-5,290	Closed	-$344K	–	1637
2019 Q4	$344K	Sell	5,290 -3,036	-36%	-$203K	﹤0.01%	1378
2019 Q3	$517K	Sell	8,326 -1,279	-13%	-$80.3K	﹤0.01%	1320
2019 Q2	$684K	Hold	9,605	–	–	﹤0.01%	1317
2019 Q1	$753K	Hold	9,605	–	–	﹤0.01%	1258
2018 Q4	$813	Buy	9,605 +4,315	+82%	+$460K	﹤0.01%	1200
2018 Q3	$906K	Buy	+5,290	New	+$798K	﹤0.01%	1276

Other funds holding LGND

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CCMLC

Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

CCA

Conestoga Capital Advisors Wayne, Pennsylvania $4.6B AUM 16.08% 1-Year Est. Return

SDJVC

St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return

Amundi Asset Management US's LGND Position: Q4 2020 in Review

Amundi Asset Management US sold out of Ligand Pharmaceuticals (LGND) in Q4 2020, closing a stake of 240 shares — an estimated $14K sold.

Amundi Asset Management US first reported a position in LGND in Q3 2018 and held it in 8 quarters. The position peaked at $906K in Q3 2018. 242 funds tracked by Wall St. Rank hold LGND as of Q4 2020.

Amundi Asset Management US reported no remaining Ligand Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
Amundi Asset Management US sold 240 Ligand Pharmaceuticals shares in Q4 2020, an estimated $14K.
Amundi Asset Management US first reported a position in Ligand Pharmaceuticals in Q3 2018 and held it in 8 quarters.
Amundi Asset Management US's Ligand Pharmaceuticals position peaked at $906K in Q3 2018.
242 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q4 2020.

Based on Amundi Asset Management US's 13F filing for Q4 2020, filed 16 Feb 2021.